Quality of life as a primary endpoint in ovarian cancer trials

Lancet Oncol. 2014 Apr;15(4):363-4. doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28.

Authors

Sven Mahner¹, Alexander Burges²

Affiliations

¹ Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: s.mahner@uke.uni-hamburg.de.
² Ludwig-Maximilians-Universität München Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Munich, Germany.

PMID: 24582485
DOI: 10.1016/S1470-2045(14)70084-1

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Ovarian Neoplasms / drug therapy*